Braidwell LP Acquires New Holdings in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Braidwell LP acquired a new position in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund acquired 515,726 shares of the company's stock, valued at approximately $12,640,000. Braidwell LP owned approximately 42.69% of Oruka Therapeutics as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of ORKA. FMR LLC acquired a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $114,763,000. Great Point Partners LLC acquired a new stake in Oruka Therapeutics during the 3rd quarter worth about $12,614,000. Finally, The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics during the third quarter valued at approximately $1,037,000. Institutional investors own 56.44% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on ORKA shares. Leerink Partners began coverage on shares of Oruka Therapeutics in a report on Tuesday, September 17th. They issued an "outperform" rating and a $44.00 price objective for the company. TD Cowen started coverage on Oruka Therapeutics in a research note on Monday, September 16th. They set a "buy" rating for the company. Jefferies Financial Group initiated coverage on shares of Oruka Therapeutics in a report on Friday, September 13th. They set a "buy" rating and a $40.00 target price for the company. Leerink Partnrs upgraded shares of Oruka Therapeutics to a "strong-buy" rating in a report on Tuesday, September 17th. Finally, Wedbush reiterated an "outperform" rating and set a $40.00 price objective on shares of Oruka Therapeutics in a research report on Tuesday, November 19th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, Oruka Therapeutics presently has an average rating of "Buy" and an average price target of $43.17.

Oruka Therapeutics Trading Up 7.3 %

Shares of ORKA traded up $1.47 during mid-day trading on Friday, reaching $21.73. The company's stock had a trading volume of 80,918 shares, compared to its average volume of 67,969. The firm's 50 day moving average price is $25.60. Oruka Therapeutics, Inc. has a 12-month low of $18.20 and a 12-month high of $53.88. The firm has a market capitalization of $760.55 million, a PE ratio of -3.47 and a beta of 0.87.

Oruka Therapeutics Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company's cardiovascular science, ARCA's management team has significant experience in developing and commercializing cardiovascular products.